Carlisle Companies Incorporated (CSL)

Cash ratio

Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020
Cash and cash equivalents US$ in thousands 753,500 576,700 400,000 324,400 897,100
Short-term investments US$ in thousands
Total current liabilities US$ in thousands 665,800 1,186,300 1,078,400 1,169,500 646,200
Cash ratio 1.13 0.49 0.37 0.28 1.39

December 31, 2024 calculation

Cash ratio = (Cash and cash equivalents + Short-term investments) ÷ Total current liabilities
= ($753,500K + $—K) ÷ $665,800K
= 1.13

The cash ratio for Carlisle Companies Incorporated has shown fluctuations over the past few years. As of December 31, 2020, the company had a cash ratio of 1.39, indicating that it had $1.39 in cash and cash equivalents for every $1 of its current liabilities. However, by December 31, 2021, the cash ratio had decreased significantly to 0.28, suggesting a decline in the company's ability to cover its short-term obligations with its available cash.

Subsequently, the cash ratio improved slightly to 0.37 as of December 31, 2022, indicating a partial recovery in the company's liquidity position. By December 31, 2023, the cash ratio further increased to 0.49, signaling an improvement in the company's ability to meet its short-term financial obligations using its cash reserves.

The latest available data as of December 31, 2024, shows a cash ratio of 1.13, which suggests that Carlisle Companies Incorporated had strengthened its liquidity position compared to the previous year. Overall, while the company experienced fluctuations in its cash ratio over the years, it seems to have managed its liquidity effectively and improved its ability to cover short-term liabilities with available cash by the end of 2024.


Peer comparison

Dec 31, 2024

Company name
Symbol
Cash ratio
Carlisle Companies Incorporated
CSL
1.13
West Pharmaceutical Services Inc
WST
0.88